| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:Levofloxacin-d8 (hydrochloride)
CAS:2699607-50-4
Purity:95% Package:1mg
|
| Company Name: |
Nanjing Shizhou Biology Technology Co.,Ltd
|
| Tel: |
17301488900 |
| Email: |
judy.xia@synzest.com |
| Products Intro: |
Product Name:Ofloxacin-D3 Hydrochloride
CAS:2699607-50-4
Purity:98% Package:1mg;5mg;10mg;100mg
|
| Company Name: |
Cayman Chemical Company
|
| Tel: |
(800) 364-9897 |
| Email: |
cayman@caymanchem.com |
| Products Intro: |
Product Name:Levofloxacin-d8 (hydrochloride)
CAS:2699607-50-4
|
|
| | INDEX NAME NOT YET ASSIGNED Basic information |
| | INDEX NAME NOT YET ASSIGNED Chemical Properties |
| solubility | DMSO: soluble | | form | A solid | | color | White to off-white |
| | INDEX NAME NOT YET ASSIGNED Usage And Synthesis |
| Description | Levofloxacin-d8 is intended for use as an internal standard for the quantification of levofloxacin by GC- or LC-MS. Levofloxacin is a fluoroquinolone antibiotic and the active stereoisomer of ofloxacin .1 It is active against S. aureus, S. epidermidis, B. subtilis, E. coli, P. aeruginosa, and K. pneumoniae (MICs = 0.25, 0.25, 0.5, 0.03, 4, and 0.25 μg/ml, respectively).2 Levofloxacin inhibits S. aureus DNA gyrase and topoisomerase IV (IC50s = 8.06 and 9.81 μg/ml, respectively).3 It eliminates infection in rat models of endocarditis caused by methicillin-sensitive or -resistant S. aureus.4 Formulations containing levofloxacin have been used in the treatment of various bacterial infections. | | References | 1. Norrby, S.R. Levofloxacin Expert Opin. Pharmacother. 1(1),109-119(1999).
2. Mohammadhosseini, N., Alipanahi, Z., Alipour, E., et al. Synthesis and antibacterial activity of novel levofloxacin derivatives containing a substituted thienylethyl moiety. Daru. 20(1),(2012).
3. Takei, M., Fukuda, H., Kishii, R., et al. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition Antimicrob. Agents Chemother. 45(12),3544-3547(2001).
4. Entenza, J.M., Vouillamoz, J., Glauser, M.P., et al. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus Antimicrob. Agents Chemother. 41(8),1662-1667(1997). |
| | INDEX NAME NOT YET ASSIGNED Preparation Products And Raw materials |
|